Predicted protein targets (top 4)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | P2RY6 | Q15077 | 8/20 | 0.66 |
| ▸ | P2RY2 | P41231 | 11/20 | 0.64 |
| ▸ | P2RY4 | P51582 | 7/20 | 0.64 |
| ▸ | P2RY14 | Q15391 | 6/20 | 0.64 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL10959520 | 1.00 | P2RY6 (0.66) | P2RY6P2RY2P2RY4P2RY14 | |
| SCHEMBL20769287 | 1.00 | P2RY6 (0.66) | P2RY6P2RY2P2RY4P2RY14 | |
| SCHEMBL2056722 | 1.00 | P2RY6 (0.66) | P2RY6P2RY2P2RY4P2RY14 | |
| SCHEMBL28920904 | 0.94 | P2RY6 (0.72) | P2RY6P2RY2P2RY4P2RY14 | |
| SCHEMBL22389513 | 0.93 | P2RY2 (0.66) | P2RY6P2RY2P2RY4P2RY14 | |
| SCHEMBL25388253 | 0.92 | P2RY6 (0.63) | P2RY6P2RY2P2RY4P2RY14 | |
| SCHEMBL18126746 | 0.91 | P2RY6 (0.59) | P2RY6P2RY2P2RY4P2RY14 | |
| SCHEMBL19546708 | 0.91 | P2RY6 (0.59) | P2RY6P2RY2P2RY4P2RY14 | |
| SCHEMBL24043084 | 0.91 | P2RY6 (0.59) | P2RY6P2RY2P2RY4P2RY14 | |
| SCHEMBL19862754 | 0.91 | P2RY6 (0.59) | P2RY6P2RY2P2RY4P2RY14 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 328 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4745239-A1 | CFB INHIBITOR COMPOSITION AND USE THEREOF | Rigerna Therapeutics Co., Ltd. (CN) | 2026-05-20 | — | — | EP | claimed |
| WO-2025031301-A1 | FTO INHIBITOR COMPOSITION AND USE THEREOF | 苏州炫景生物科技有限公司 | 2025-02-13 | — | — | WO | claimed |
| WO-2025026228-A1 | CFB INHIBITOR COMPOSITION AND USE THEREOF | 苏州炫景生物科技有限公司 | 2025-02-06 | — | — | WO | claimed |
| WO-2024027809-A1 | RNA INHIBITOR FOR INHIBITING APOC3 GENE EXPRESSION AND USE THEREOF | 厦门甘宝利生物医药有限公司 | 2024-02-08 | — | — | WO | claimed |
| US-11884919-B2 | Lipid formulated compositions and methods for inhibiting expression of serum amyloid a gene | ALNYLAM PHARMACEUTICALS, INC. (US) | 2024-01-30 | — | — | US | claimed |
| US-20230304058-A1 | NOVEL 5'CAP ANALOG HAVING CAP2 STRUCTURE AND PREPARATION METHOD THEREFOR | SHENZHEN RHEGEN BIOTECHNOLOGY CO., LTD. (CN) | 2023-09-28 | — | — | US | claimed |
| WO-2023169548-A1 | LPA INHIBITOR AND USE THEREOF | 厦门甘宝利生物医药有限公司 | 2023-09-14 | — | — | WO | claimed |
| EP-4202053-A1 | NOVEL 5'CAP ANALOG HAVING CAP2 STRUCTURE AND PREPARATION METHOD THEREFOR | Shenzhen Rhegen Biotechnology Co., Ltd. (CN) | 2023-06-28 | — | — | EP | claimed |
| US-20220243199-A1 | LIPID FORMULATED COMPOSITIONS AND METHODS FOR INHIBITING EXPRESSION OF SERUM AMYLOID A GENE | BANK OF AMERICA, N.A. | 2022-08-04 | — | — | US | claimed |
| WO-2022036858-A1 | NOVEL 5'CAP ANALOG HAVING CAP2 STRUCTURE AND PREPARATION METHOD THEREFOR | 深圳市瑞吉生物科技有限公司 | 2022-02-24 | — | — | WO | claimed |
| US-20160194633-A1 | Lipid Formulated Compositions and Methods for Inhibiting Expression of Serum Amyloid A Gene | BANK OF AMERICA, N.A. | 2016-07-07 | — | — | US | claimed |
| EP-2334793-B1 | COMPOSITIONS AND METHODS FOR INHIBITING EXPRESSION OF SERUM AMYLOID A GENE | ALNYLAM PHARMACEUTICALS INC (US) | 2016-04-06 | — | — | EP | claimed |
| EP-2905336-A1 | Compositions and methods for inhibiting expression of a gene from the ebola | Alnylam Pharmaceuticals Inc. (US) | 2015-08-12 | — | — | EP | claimed |
| EP-2589660-B1 | Compositions and methods for inhibiting expression of a gene from the Ebola | ALNYLAM PHARMACEUTICALS INC (US) | 2014-11-26 | — | — | EP | claimed |
| EP-2147102-B1 | COMPOSITIONS AND METHODS FOR INHIBITING EXPRESSION OF A GENE FROM THE EBOLA | ALNYLAM PHARMACEUTICALS INC (US) | 2014-01-15 | — | — | EP | claimed |
| EP-2589660-A1 | Compositions and methods for inhibiting expression of a gene from the Ebola | Alnylam Pharmaceuticals Inc. (US) | 2013-05-08 | — | — | EP | claimed |
| EP-2334793-A1 | LIPID FORMULATED COMPOSITIONS AND METHODS FOR INHIBITING EXPRESSION OF SERUM AMYLOID A GENE | Alnylam Pharmaceuticals, Inc. (US) | 2011-06-22 | — | — | EP | claimed |
| US-7846908-B2 | RNAi modulation of TGF-beta and therapeutic uses thereof | ALNYLAM PHARMACEUTICALS, INC. (US) | 2010-12-07 | — | — | US | claimed |
| WO-2010036962-A1 | LIPID FORMULATED COMPOSITIONS AND METHODS FOR INHIBITING EXPRESSION OF SERUM AMYLOID A GENE | ALNYLAM PHARMACEUTICALS, INC. (US) | 2010-04-01 | — | — | WO | claimed |
| US-4507089-A | Mechanical support module for nucleic acid | TCHUEMPE TCHUENTE GERMAIN (FR) | 1985-03-26 | — | — | US | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11884919-B2 | Lipid formulated compositions and methods for inhibiting expression of serum amyloid a gene | SAAL1, APOB, SCARB1 | P2RY6 4176/4885P2RY2 4259/4885P2RY4 4616/4885 |
| US-20230304058-A1 | NOVEL 5'CAP ANALOG HAVING CAP2 STRUCTURE AND PREPARATION METHOD THEREFOR | RNGTT, CAPG, CPSF7 | P2RY6 2979/4885P2RY2 2207/4885P2RY4 3022/4885 |
| US-20220243199-A1 | LIPID FORMULATED COMPOSITIONS AND METHODS FOR INHIBITING EXPRESSION OF SERUM AMYLOID A GENE | SAAL1, APOB, HNRNPAB | P2RY6 4338/4885P2RY2 4349/4885P2RY4 4679/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.